1.
Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug
Performance Despite Large Market Opportunity
GBI Research
Report Highlight

2.
About the Publisher
GBI Research provides industry-leading global business intelligence solutions. Our products and services
help companies make better business decisions, win business and position themselves more effectively.
GBI Research publishes more than 100 research reports per annum across a wide range of industries.
Our reports draw on in-depth primary and secondary research, databases of proprietary in-house data
and high quality analysis from our expert teams. GBI Research employs hundreds of highly qualified
Analysts across the US, Europe and Asia.
Key report types currently published by GBI Research include:
•Market Intelligence Reports: premium analytical reports based on a combination of market data,
company, deals and project content, industry surveys and additional primary and secondary research.
•Benchmarking Reports: analytical reports comparing key financial indicators for the top 20 companies
in a particular industry and geography.
•Industry Outlook Reports: survey-based reports, revealing and analyzing the leading experts' opinions
on the future of the industry covered.
•Market Profiles: overview-level reports based on market, company and demographic data.
•Pipeline Analysis Reports: reports analyzing the unmet need, market size and product pipeline for
different disease indications, based on a detailed database of developmental products.

3.
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Obesity Therapeutics
to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often
described as a global endemic, with incidence dramatically increasing over the past decades, particularly in
developed countries. Being overweight or obese is a major risk factor in the development of many chronic
diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic
and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll
Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the
market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use.
As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a
major barrier to the growth of the anti-obesity therapeutics market.
Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a
placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July
2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average
placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market,
providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and
other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion.
Although moderate, this is significantly below the market potential given the size of the prevalence population.
Optimally safe and effective anti-obesity drugs which overcome healthcare professionals’ negative opinions will
have to be developed if the size of the market is ever to reflect the prevalence of obesity.

4.
View This Report
•The report analyzes the incidence of obesity, current treatment options, pipeline and market
forecasts, and deals surrounding anti-obesity drugs.
•A brief introduction to obesity; detailed analysis of recent, current and projected incidence
trends; co-morbidities; economic implications of their treatment; and the current treatment
options
•Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety
and efficacy data, and a discussion of each drug’s expected performance within the forecast
period
•Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule
type and mechanism of action
•Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type
•An in-depth forecast model for the anti-obesity drugs market in the US, UK, France,
Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance
of marketed drugs and those expected to be approved within the forecast period, and takes
into account drug cost, efficacy, safety, and likely prescription volumes.
•A detailed discussion of the drivers and barriers for this immature market.
Scope

5.
View More Reports from this Publisher
Title Date
Compression Therapy Market to 2019 - Growth due to Increased Awareness in
Venous Disease Management Offset by Reimbursement Issues Sept 1, 2013
Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing
Efficacy, and Pipeline Innovation Combine to Drive Growth July 31, 2013
Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced
New Combination Products Forecast to Capture Significant Market Share and Drive
Growth June 30, 2013
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially
Supplemented by Approvals for Alzheimer’s Disease May 14, 2013
X-ray Systems Market to 2019 - Enhanced Imaging Capability, Better Procedural
Efficiency and Portability to Drive Future Growth of Digital X-ray Systems April 8, 2013
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD
Offer Hope for Higher Rates of Treatment April 30, 2013
Critical Care Market to 2019 - Growth from Factor Concentrates New Indications
and Increasing Demand for Albumin in Asia-Pacific May 14, 2013
Advanced Wound Management Market to 2019 - Increasing Incidence of Diabetes
Leading to Chronic Wounds in Emerging Countries will Drive Future Growth June 3, 2013

6.
MarketResearch.com provides market research solutions to business professionals
seeking to enhance their business goals. We provide a number of business intelligence
solutions, from individual market research reports from over 700 leading global
publishers, to Knowledge Centers where clients can discover deeper business insight
products into a topic over time. Or perhaps your business needs a much wider view across
multiple industries and topics, if so, our Profound solution allows you to select specific
parts (graphs, tables, charts or sections) from different market research reports.
Our Account Managers have in-depth knowledge of the publishers and the various types
of reports in their respective industries. They give you unbiased and qualitative insights on
which reports will best meet your needs.
If you are interested in expanding your business or growing your market share, contact us
to get a free Consultation to Assess your Market Research Needs. We can help tailor a
solution that suits your unique business goals. One of our Account Managers will get right
back in touch with you.
About Us

7.
For More on this Report and Additional Research
Visit MarketResearch.com
Or call
1-800-298-5699